CD112 (Nectin-2) and CD155 (Poliovirus receptor) (CD112 (Nectin-2), CD155 (PVR))

CD112 (Nectin-2) and CD155 (Poliovirus receptor) are transmembrane cell adhesion molecules in the immunoglobulin superfamily—nectin and nectin-like families, respectively. They act as critical ligands for immune checkpoint receptors (including TIGIT, CD96, CD112R, and CD226) on T cells and natural killer cells, controlling immune cell activation and inhibition. Both are widely expressed on epithelial, endothelial, neuronal, and immune cells, and are frequently upregulated in tumor cells. Their interaction with immune checkpoints modulates anti-tumor immune responses and has made them promising targets for cancer immunotherapy. High levels are prognostic of poor outcomes in several cancers, and they drive tumor growth, invasion, and immune evasion. Drug development currently focuses on blocking the inhibitory signaling mediated through their checkpoint pathways to restore immune function against tumors.

Other names

Nectin-2PVR-related protein 2PVRL2PVRNECL-5Nectin-like molecule 5

Immune checkpoint inhibition: Blocking CD112/CD155 interaction with receptors like TIGIT, CD112R, and CD226 to enhance T and NK cell anti-tumor activity. Ligand blockade or immune cell activation: Antagonists or antibodies prevent inhibitory signaling through these axes, restoring immune cell function.